Search

Background As diagnostic tests for COVID-19 were broadly deployed under Emergency Use Authorization, there emerged a need to understand the real-world utilization and performance of serological testing across the United States. Methods Six health systems contributed electronic health records and/or claims data, jointly developed a master protocol, and used it to execute the analysis in parallel. We used descriptive statistics to examine demographic, clinical, and geographic characteristics of serology testing among patients with RNA positive for SARS-CoV-2. Results Across datasets, we observed 930,669 individuals with positive RNA for SARS-CoV-2. Of these, 35,806 (4%) were serotested within 90 days; 15% of which occurred 30%) in some datasets—limiting our ability to examine differences in serological testing by race. In datasets where race/ethnicity information was available, we observed a greater distribution of White individuals among those serotested; however, the time between RNA and serology tests appeared shorter in Black compared to White individuals. Test manufacturer data was available in half of the datasets contributing to the analysis. Conclusion Our results inform the underlying context of serotesting during the first year of the COVID-19 pandemic and differences observed between claims and EHR data sources–a critical first step to understanding the real-world accuracy of serological tests. Incomplete reporting of race/ethnicity data and a limited ability to link test manufacturer data, lab results, and clinical data challenge the ability to assess the real-world performance of SARS-CoV-2 tests in different contexts and the overall U.S. response to current and future disease pandemics.

Objectives: To examine the effects of computerized requests for pharmacist-to-dose (PTD), an advanced clinical decision support tool for dosing guidance, on antimicrobial therapy with vancomycin and aminoglycosides, describe PTD request utilization, and identify factors that may prolong this process. Design: A retrospective review was conducted of patients hospitalized from Jan 2004 to Jun 2006 with suspected pneumonia who received vancomycin, tobramycin, or gentamicin via PTD (study) or routine provider order entry (control). Measurements: The primary endpoint was time to pharmacist completion of PTD request. Secondary data points included medication turn-around times for first doses of vancomycin or aminoglycosides and for first doses of any antibiotic, dose adjustment for renal dysfunction, medication errors, and time of order entry. Multivariate analysis was conducted to identify predictors of total time to pharmacist verification and time to administration of first doses of vancomycin or aminoglycosides. Results: Median time for pharmacist completion of PTD requests was 29 minutes. Delays were noted in the study group (n 49) by comparison with the control group (n 48) for median time to first dose of vancomycin or aminoglycoside (185 vs. 138 min, p 0.45) and for any antibiotic (134 vs. 118 min, p 0.42), respectively. Fewer medication errors were reported in the study group (5 vs. 18 errors, p 0.002). In a multivariate model, PTD was not significantly predictive of time to pharmacy verification or medication turn-around time. Conclusions: Pharmacists completed pharmacist-to-dose consultations for dosing guidance of vancomycin and aminoglycosides within a median of 30 minutes. Implementation of a computerized request for clinical pharmacists to provide medication-related clinical decision support increased medication turn-around time of vancomycin and aminoglycosides and reduced medication errors. Consultation of clinical pharmacists by computerized request for initial antibiotic dosing of medications with narrow therapeutic windows is an option for medication-related clinical decision support but providers should be aware that consultation may delay medication turn-around time.

Background Depressive symptoms are common in seniors and may predict dementia. The objective of this study was to evaluate multiple measures of depressive symptoms to determine whether they predict subsequent Alzheimer's disease (AD) or dementia. Methods This population-based cohort study with 5-year follow-up included 766 community-dwelling seniors (ages 65+ years) in Manitoba, Canada. Measurements considered were the Center for Epidemiologic Studies Depression (CES-D) scale, participant-reported medical history, and duration of depression. Results Total CES-D score was a significant predictor of AD and dementia when categorized as a dichotomous variable according to the cutoff scores of 16 and 17; a CES-D cutoff of 21 was a significant predictor of AD and a marginally significant predictor of dementia. When analyzed as a continuous variable, CES-D score was marginally predictive of AD and dementia. Neither participant-reported history of depression nor participant-reported duration of depression was significant in predicting AD or dementia. Conclusion Because depressive symptoms as measured by the CES-D predict the development of AD and dementia over 5 years, clinicians should monitor their older patients with these symptoms for signs of cognitive impairment.